Abstract
An endothelial cell inhibitor was purified from supernatant of an Epstein-Barr virus-immortalized cell line and identified as fragments of calreticulin. The purified recombinant NH2-terminal domain of calreticulin (amino acids 1-180) inhibited the proliferation of endothelial cells, but not cells of other lineages, and suppressed angiogenesis in vivo. We have named this NH2-terminal domain of calreticulin vasostatin. When inoculated into athymic mice, vasostatin significantly reduced growth of human Burkitt lymphoma and human colon carcinoma. Compared with other inhibitors of angiogenesis, vasostatin is a small, soluble, and stable molecule that is easy to produce and deliver. As an angiogenesis inhibitor that specifically targets proliferating endothelial cells, vasostatin has a unique potential for cancer treatment.
Original language | English |
---|---|
Pages (from-to) | 2349-2356 |
Number of pages | 8 |
Journal | Journal of Experimental Medicine |
Volume | 188 |
Issue number | 12 |
DOIs | |
State | Published - 1998 |
Externally published | Yes |
Keywords
- Angiogenesis
- Antitumor agent
- Cancer
- Cell growth
- Endothelial cells